Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01269281 | Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions | PHASE1 | COMPLETED | 50 | — | — | Jul 1, 2005 | Jul 1, 2005 | Jan 4, 2011 | 1 | India |
| Arm | Type | Description |
|---|---|---|
| Sumatriptan Succinate tablets 100 mg | EXPERIMENTAL | Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited |
| Imitrex 100 mg Tablets | ACTIVE_COMPARATOR | Imitrex 100 mg Tablets of Glaxosmithkline |
| Name | Type | Description |
|---|---|---|
| Sumatriptan | DRUG | Sumatriptan Succinate Tablets 100 mg |
Inclusion Criteria: 1. The subjects should be healthy males between 18 and 45 years. 2. The subjects should be screened within 21 days prior to the administration of first dose of the study.. 3. The subjects should have a BMI between 18 and 25 kg/m2 4. The subjects should be able to communicate eff...